Pulmatrix Inc (PULM)
1.890
0.00 (0.00%)
USD |
NASDAQ |
May 08, 16:00
Pulmatrix Research and Development Expense (Quarterly): 3.516M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.516M |
| September 30, 2023 | 3.963M |
| June 30, 2023 | 4.165M |
| March 31, 2023 | 3.874M |
| December 31, 2022 | 4.467M |
| September 30, 2022 | 5.287M |
| June 30, 2022 | 4.337M |
| March 31, 2022 | 4.149M |
| December 31, 2021 | 2.959M |
| September 30, 2021 | 4.026M |
| June 30, 2021 | 4.541M |
| March 31, 2021 | 3.856M |
| December 31, 2020 | 3.265M |
| September 30, 2020 | 3.873M |
| June 30, 2020 | 3.184M |
| March 31, 2020 | 5.287M |
| December 31, 2019 | 4.208M |
| September 30, 2019 | 3.297M |
| June 30, 2019 | 3.164M |
| March 31, 2019 | 2.176M |
| December 31, 2018 | 2.676M |
| September 30, 2018 | 3.056M |
| June 30, 2018 | 4.013M |
| March 31, 2018 | 3.221M |
| Date | Value |
|---|---|
| December 31, 2017 | 2.589M |
| September 30, 2017 | 2.618M |
| June 30, 2017 | 3.363M |
| March 31, 2017 | 1.672M |
| December 31, 2016 | 2.774M |
| September 30, 2016 | 1.507M |
| June 30, 2016 | 2.441M |
| March 31, 2016 | 3.43M |
| December 31, 2015 | 2.466M |
| September 30, 2015 | 2.193M |
| June 30, 2015 | 1.61M |
| March 31, 2015 | 0.254M |
| December 31, 2014 | 0.619M |
| September 30, 2014 | 0.629M |
| June 30, 2014 | 0.676M |
| March 31, 2014 | 0.317M |
| December 31, 2013 | 0.395M |
| September 30, 2013 | 0.495M |
| June 30, 2013 | 0.175M |
| March 31, 2013 | 0.202M |
| December 31, 2012 | 0.033M |
| September 30, 2012 | 0.013M |
| June 30, 2012 | 0.01M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.959M
Minimum
Dec 2021
5.287M
Maximum
Mar 2020
3.969M
Average
3.963M
Median
Sep 2023
Research and Development Expense (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 4.196M |
| Oragenics Inc | 11.04M |